Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 4 Business Days
Erectile Dysfunction Drugs Market Growth & Trends
The global erectile dysfunction drugs market size is expected to reach USD 4.8 billion by 2030, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 8.5% from 2022 to 2030. Increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of aged 40 years male population and 49.0% by age 70 years are affected by erectile dysfunction. Thus, increasing geriatric population is anticipated to increase prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada which may require registration for this program. Thus, presence of such supportive programs for branded version of Cialis may increase the affordability of lower income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc., and continuing product supply.
Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda’s (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease and lack of discretion may restrain market growth.As per the survey conducted by European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.
Erectile Dysfunction Drugs Market Report Highlights
Erectile Dysfunction Drugs Market Growth & Trends
The global erectile dysfunction drugs market size is expected to reach USD 4.8 billion by 2030, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 8.5% from 2022 to 2030. Increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of aged 40 years male population and 49.0% by age 70 years are affected by erectile dysfunction. Thus, increasing geriatric population is anticipated to increase prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada which may require registration for this program. Thus, presence of such supportive programs for branded version of Cialis may increase the affordability of lower income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc., and continuing product supply.
Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda’s (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease and lack of discretion may restrain market growth.As per the survey conducted by European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.
Erectile Dysfunction Drugs Market Report Highlights
- By product, the viagra segment held the largest market share in 2021 due to worldwide availability of Viagra and increased awareness about the product among ED patients
- The cialis segment held the second largest market share in 2021 due to strategic initiatives undertaken by key companies for the development and commercialization of Cialis. In March 2022, the Saudi Chemical Co. Holding (SCCH) acquired Eli Lilly’s Cialis brand in Saudi Arabia
- Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of region is attributable to the entry of new products into the region. For instance, in July 2021, Menarini Asia-Pacific Holdings Pte. Ltd acquired Eli Lilly’s Cialis in China
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 ERECTILE DYSFUNCTION DRUGS MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Covid Impact Analysis
3.5 Market Dynamics
3.6 Market Driver Impact Analysis
3.6.1 Increasing prevalence of erectile dysfunction
3.6.2 Increasing product approval and launches
3.6.3 Supportive reimbursement policies
3.7 Market Restraint Analysis
3.7.1 Lack of healthcare infrastructure and manufacturing errors
3.7.2 Lack of awareness about disease
3.8 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.9 Porter’s Five Forces Analysis
CHAPTER 4 ERECTILE DYSFUNCTION DRUGS MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Erectile Dysfunction Drugs Market: Product Movement Analysis
4.1.1 Viagra
4.1.1.1 Viagra market estimates and forecast, 2018 - 2030
4.1.2 Cialis
4.1.2.1 Cialis market estimates and forecast, 2018 - 2030
4.1.3 Zydena
4.1.3.1 Zydena market estimates and forecast, 2018 - 2030
4.1.4 Levitra
4.1.4.1 Levitra market estimates and forecast, 2018 - 2030
4.1.5 Stendra
4.1.5.1 Stendra market estimates and forecast, 2018 - 2030
4.1.6 Others
4.1.6.1 Others market estimates and forecast, 2018 - 2030
CHAPTER 5 ERECTILE DYSFUNCTION DRUGS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
5.1 Regional Market Share Analysis, 2021 & 2030
5.2 Regional Market Snapshot
5.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2021 to 2030
5.3.1 North America
5.3.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
5.3.1.2 U.S.
5.3.1.2.1 U.S. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.1.3 Canada
5.3.1.3.1 Canada Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2 Europe
5.3.2.1 Europe Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.2 U.K.
5.3.2.2.1 U.K. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.3 Germany
5.3.2.3.1 Germany Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.4 Spain
5.3.2.4.1 Spain Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.5 France
5.3.2.5.1 France Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.6 Italy
5.3.2.6.1 Italy Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3 Asia Pacific
5.3.3.1 Asia Pacific Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.2 Japan
5.3.3.2.1 Japan Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.3 China
5.3.3.3.1 China Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.4 India
5.3.3.4.1 India Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.5 Australia
5.3.3.5.1 Australia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4 Latin America
5.3.4.1 Latin America Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.2 Brazil
5.3.4.2.1 Brazil Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.3 Mexico
5.3.4.3.1 Mexico Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.4 Argentina
5.3.4.4.1 Argentina Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5 MEA
5.3.5.1 MEA Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.2 South Africa
5.3.5.2.1 South Africa Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.3 Saudi Arabia
5.3.5.3.1 Saudia Arabia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.4 UAE
5.3.5.4.1 UAE Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
CHAPTER 6 ERECTILE DYSFUNCTION DRUGS MARKET: COMPETITIVE ANALYSIS
6.1 Recent Developments and Impact Analysis, by Key Market Participants
6.1.1 Synergy Analysis: Major Deals and Strategic Alliances
6.1.1.1 New Product Launches
6.1.1.2 Mergers and Acquisitions
6.1.1.3 Licensing Agreements
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.2.3 Emerging Players
6.2.4 Heat map analysis
6.3 Company Market Position Analysis
6.4 Vendor Landscape
6.4.1 List of key distributors and channel partners
6.4.2 List of Potential End-Users
6.4.3 Key Company Market Share Analysis, 2021
6.4.4 Consumer Behavior Analysis
6.4.5 Competitive Dashboard Analysis
6.5 Private Companies
6.5.1 List of key emerging companies
6.5.2 Regional Network Map
6.6 Company Profiles
6.6.1 Pfizer, Inc.
6.6.1.1 Company overview
6.6.1.2 Financial Performance
6.6.1.3 Product benchmarking
6.6.1.4 Strategic initiatives
6.6.2 Eli Lilly and Company
6.6.2.1 Company overview
6.6.2.2 Financial Performance
6.6.2.3 Product benchmarking
6.6.2.4 Strategic initiatives
6.6.3 Teva Pharmaceutical Industries Ltd
6.6.3.1 Company overview
6.6.3.2 Financial Performance
6.6.3.3 Product benchmarking
6.6.3.4 Strategic initiatives
6.6.4 Sanofi
6.6.4.1 Company overview
6.6.4.2 Financial Performance
6.6.4.3 Product benchmarking
6.6.4.4 Strategic initiatives
6.6.5 Sun Pharmaceutical Industries Ltd
6.6.5.1 Company overview
6.6.5.2 Financial Performance
6.6.5.3 Product benchmarking
6.6.5.4 Strategic initiatives
6.6.6 Bayer AG
6.6.6.1 Company overview
6.6.6.2 Financial Performance
6.6.6.3 Product benchmarking
6.6.6.4 Strategic initiatives
6.6.7 Petros Pharmaceuticals, Inc.
6.6.7.1 Company overview
6.6.7.2 Financial Performance
6.6.7.3 Product benchmarking
6.6.7.4 Strategic initiatives
6.6.8 VIVUS, Inc.
6.6.8.1 Company overview
6.6.8.2 Financial Performance
6.6.8.3 Product benchmarking
6.6.8.4 Strategic initiatives
6.6.9 Auxilium Pharmaceuticals, Inc.
6.6.9.1 Company overview
6.6.9.2 Financial Performance
6.6.9.3 Product benchmarking
6.6.9.4 Strategic initiatives
6.6.10 Adamed
6.6.10.1 Company overview
6.6.10.2 Financial Performance
6.6.10.3 Product benchmarking
6.6.10.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 ERECTILE DYSFUNCTION DRUGS MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.4 Covid Impact Analysis
3.5 Market Dynamics
3.6 Market Driver Impact Analysis
3.6.1 Increasing prevalence of erectile dysfunction
3.6.2 Increasing product approval and launches
3.6.3 Supportive reimbursement policies
3.7 Market Restraint Analysis
3.7.1 Lack of healthcare infrastructure and manufacturing errors
3.7.2 Lack of awareness about disease
3.8 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.9 Porter’s Five Forces Analysis
CHAPTER 4 ERECTILE DYSFUNCTION DRUGS MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD MILLION)
4.1 Erectile Dysfunction Drugs Market: Product Movement Analysis
4.1.1 Viagra
4.1.1.1 Viagra market estimates and forecast, 2018 - 2030
4.1.2 Cialis
4.1.2.1 Cialis market estimates and forecast, 2018 - 2030
4.1.3 Zydena
4.1.3.1 Zydena market estimates and forecast, 2018 - 2030
4.1.4 Levitra
4.1.4.1 Levitra market estimates and forecast, 2018 - 2030
4.1.5 Stendra
4.1.5.1 Stendra market estimates and forecast, 2018 - 2030
4.1.6 Others
4.1.6.1 Others market estimates and forecast, 2018 - 2030
CHAPTER 5 ERECTILE DYSFUNCTION DRUGS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
5.1 Regional Market Share Analysis, 2021 & 2030
5.2 Regional Market Snapshot
5.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2021 to 2030
5.3.1 North America
5.3.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
5.3.1.2 U.S.
5.3.1.2.1 U.S. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.1.3 Canada
5.3.1.3.1 Canada Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2 Europe
5.3.2.1 Europe Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.2 U.K.
5.3.2.2.1 U.K. Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.3 Germany
5.3.2.3.1 Germany Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.4 Spain
5.3.2.4.1 Spain Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.5 France
5.3.2.5.1 France Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.2.6 Italy
5.3.2.6.1 Italy Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3 Asia Pacific
5.3.3.1 Asia Pacific Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.2 Japan
5.3.3.2.1 Japan Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.3 China
5.3.3.3.1 China Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.4 India
5.3.3.4.1 India Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.3.5 Australia
5.3.3.5.1 Australia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4 Latin America
5.3.4.1 Latin America Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.2 Brazil
5.3.4.2.1 Brazil Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.3 Mexico
5.3.4.3.1 Mexico Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.4.4 Argentina
5.3.4.4.1 Argentina Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5 MEA
5.3.5.1 MEA Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.2 South Africa
5.3.5.2.1 South Africa Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.3 Saudi Arabia
5.3.5.3.1 Saudia Arabia Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
5.3.5.4 UAE
5.3.5.4.1 UAE Erectile Dysfunction Drugs market, 2018 - 2030 (USD Million)
CHAPTER 6 ERECTILE DYSFUNCTION DRUGS MARKET: COMPETITIVE ANALYSIS
6.1 Recent Developments and Impact Analysis, by Key Market Participants
6.1.1 Synergy Analysis: Major Deals and Strategic Alliances
6.1.1.1 New Product Launches
6.1.1.2 Mergers and Acquisitions
6.1.1.3 Licensing Agreements
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.2.3 Emerging Players
6.2.4 Heat map analysis
6.3 Company Market Position Analysis
6.4 Vendor Landscape
6.4.1 List of key distributors and channel partners
6.4.2 List of Potential End-Users
6.4.3 Key Company Market Share Analysis, 2021
6.4.4 Consumer Behavior Analysis
6.4.5 Competitive Dashboard Analysis
6.5 Private Companies
6.5.1 List of key emerging companies
6.5.2 Regional Network Map
6.6 Company Profiles
6.6.1 Pfizer, Inc.
6.6.1.1 Company overview
6.6.1.2 Financial Performance
6.6.1.3 Product benchmarking
6.6.1.4 Strategic initiatives
6.6.2 Eli Lilly and Company
6.6.2.1 Company overview
6.6.2.2 Financial Performance
6.6.2.3 Product benchmarking
6.6.2.4 Strategic initiatives
6.6.3 Teva Pharmaceutical Industries Ltd
6.6.3.1 Company overview
6.6.3.2 Financial Performance
6.6.3.3 Product benchmarking
6.6.3.4 Strategic initiatives
6.6.4 Sanofi
6.6.4.1 Company overview
6.6.4.2 Financial Performance
6.6.4.3 Product benchmarking
6.6.4.4 Strategic initiatives
6.6.5 Sun Pharmaceutical Industries Ltd
6.6.5.1 Company overview
6.6.5.2 Financial Performance
6.6.5.3 Product benchmarking
6.6.5.4 Strategic initiatives
6.6.6 Bayer AG
6.6.6.1 Company overview
6.6.6.2 Financial Performance
6.6.6.3 Product benchmarking
6.6.6.4 Strategic initiatives
6.6.7 Petros Pharmaceuticals, Inc.
6.6.7.1 Company overview
6.6.7.2 Financial Performance
6.6.7.3 Product benchmarking
6.6.7.4 Strategic initiatives
6.6.8 VIVUS, Inc.
6.6.8.1 Company overview
6.6.8.2 Financial Performance
6.6.8.3 Product benchmarking
6.6.8.4 Strategic initiatives
6.6.9 Auxilium Pharmaceuticals, Inc.
6.6.9.1 Company overview
6.6.9.2 Financial Performance
6.6.9.3 Product benchmarking
6.6.9.4 Strategic initiatives
6.6.10 Adamed
6.6.10.1 Company overview
6.6.10.2 Financial Performance
6.6.10.3 Product benchmarking
6.6.10.4 Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Regulatory framework
Table 4 Average annual prices for Viagra (Brand) & Sildenafil Citrate (Generic)
Table 5 Average annual prices for Cialis (Brand) & Tadalafil (Generic)
Table 6 Average annual prices for Levitra (Brand) & Vardenafil HCL (Generic)
Table 7 List of parameters
Table 8 List of distributors
Table 9 North America erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 10 U.S. erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 11 Canada erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 12 Europe erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 13 U.K. erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 14 Germany erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 15 France erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 16 Italy erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 17 Spain erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 18 Asia Pacific erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 19 Japan erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 20 China erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 21 India erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 22 Australia erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 23 South Korea erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 24 Latin America erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 25 Brazil erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 26 Mexico erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 27 Argentina erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 28 MEA erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 29 South Africa erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 30 Saudi Arabia erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 31 UAE erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 32 List of key distributors
Table 33 List of key emerging companies/technology disruptors/innovators
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Regulatory framework
Table 4 Average annual prices for Viagra (Brand) & Sildenafil Citrate (Generic)
Table 5 Average annual prices for Cialis (Brand) & Tadalafil (Generic)
Table 6 Average annual prices for Levitra (Brand) & Vardenafil HCL (Generic)
Table 7 List of parameters
Table 8 List of distributors
Table 9 North America erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 10 U.S. erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 11 Canada erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 12 Europe erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 13 U.K. erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 14 Germany erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 15 France erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 16 Italy erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 17 Spain erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 18 Asia Pacific erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 19 Japan erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 20 China erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 21 India erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 22 Australia erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 23 South Korea erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 24 Latin America erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 25 Brazil erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 26 Mexico erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 27 Argentina erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 28 MEA erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 29 South Africa erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 30 Saudi Arabia erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 31 UAE erectile dysfunction drugs market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 32 List of key distributors
Table 33 List of key emerging companies/technology disruptors/innovators
LIST OF FIGURES
Fig. 1 Erectile Dysfunction Drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Commodity flow approach
Fig. 10 Market outlook (2021) (USD Million)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Antibody drug conjugates market driver impact
Fig. 13 Antibody drug conjugates market restraint impact
Fig. 14 SWOT analysis, by factor (political & legal economic and technological)
Fig. 15 Porter’s five forces analysis
Fig. 16 Erectile dysfunction drugs product outlook: Key takeaways
Fig. 17 Erectile dysfunction drugs market: Product movement analysis
Fig. 18 Viagra market estimates and forecasts, 2018 - 2030
Fig. 19 Cialis market estimates and forecasts, 2018 - 2030
Fig. 20 Zydena market estimates and forecasts, 2018 - 2030
Fig. 21 Levitra market estimates and forecasts, 2018 - 2030
Fig. 22 Stendra market estimates and forecasts, 2018 - 2030
Fig. 23 Others market estimates and forecasts, 2018 - 2030
Fig. 24 Regional outlook, 2021 & 2030
Fig. 25 Regional marketplace: Key takeaways
Fig. 26 North America
Fig. 27 North America erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 28 U.S.
Fig. 29 U.S. erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 30 Canada
Fig. 31 Canada erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 32 Europe
Fig. 33 Europe erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 34 U.K.
Fig. 35 U.K. erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 36 Germany
Fig. 37 Germany erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 38 Spain
Fig. 39 Spain erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 40 France
Fig. 41 France erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 42 Italy
Fig. 43 Italy erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific
Fig. 45 Asia Pacific erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 46 Japan
Fig. 47 Japan erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 48 China
Fig. 49 China erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 50 India
Fig. 51 India erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 52 Australia
Fig. 53 Australia erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 54 South Korea
Fig. 55 South Korea erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 56 Latin America
Fig. 57 Latin America erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 58 Brazil
Fig. 59 Brazil erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 60 Mexico
Fig. 61 Mexico erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 62 Argentina
Fig. 63 Argentina erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 64 Middle East & Africa
Fig. 65 MEA erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 66 South Africa
Fig. 67 South Africa erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 68 Saudi Arabia
Fig. 69 Saudi Arabia erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 70 UAE
Fig. 71 UAE erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 72 Heat map analysis
Fig. 73 Company market position analysis, 2021
Fig. 74 Company market position analysis, 2021
Fig. 75 Company market share analysis (2021)
Fig. 76 Consumer behavior analysis
Fig. 77 Market differentiators
Fig. 1 Erectile Dysfunction Drugs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Commodity flow approach
Fig. 10 Market outlook (2021) (USD Million)
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Antibody drug conjugates market driver impact
Fig. 13 Antibody drug conjugates market restraint impact
Fig. 14 SWOT analysis, by factor (political & legal economic and technological)
Fig. 15 Porter’s five forces analysis
Fig. 16 Erectile dysfunction drugs product outlook: Key takeaways
Fig. 17 Erectile dysfunction drugs market: Product movement analysis
Fig. 18 Viagra market estimates and forecasts, 2018 - 2030
Fig. 19 Cialis market estimates and forecasts, 2018 - 2030
Fig. 20 Zydena market estimates and forecasts, 2018 - 2030
Fig. 21 Levitra market estimates and forecasts, 2018 - 2030
Fig. 22 Stendra market estimates and forecasts, 2018 - 2030
Fig. 23 Others market estimates and forecasts, 2018 - 2030
Fig. 24 Regional outlook, 2021 & 2030
Fig. 25 Regional marketplace: Key takeaways
Fig. 26 North America
Fig. 27 North America erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 28 U.S.
Fig. 29 U.S. erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 30 Canada
Fig. 31 Canada erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 32 Europe
Fig. 33 Europe erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 34 U.K.
Fig. 35 U.K. erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 36 Germany
Fig. 37 Germany erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 38 Spain
Fig. 39 Spain erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 40 France
Fig. 41 France erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 42 Italy
Fig. 43 Italy erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific
Fig. 45 Asia Pacific erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 46 Japan
Fig. 47 Japan erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 48 China
Fig. 49 China erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 50 India
Fig. 51 India erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 52 Australia
Fig. 53 Australia erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 54 South Korea
Fig. 55 South Korea erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 56 Latin America
Fig. 57 Latin America erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 58 Brazil
Fig. 59 Brazil erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 60 Mexico
Fig. 61 Mexico erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 62 Argentina
Fig. 63 Argentina erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 64 Middle East & Africa
Fig. 65 MEA erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 66 South Africa
Fig. 67 South Africa erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 68 Saudi Arabia
Fig. 69 Saudi Arabia erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 70 UAE
Fig. 71 UAE erectile dysfunction drugs market, 2018 - 2030 (USD Million)
Fig. 72 Heat map analysis
Fig. 73 Company market position analysis, 2021
Fig. 74 Company market position analysis, 2021
Fig. 75 Company market share analysis (2021)
Fig. 76 Consumer behavior analysis
Fig. 77 Market differentiators
